VTRS vs. PFE

Last updated Apr 1, 2026

Compare and contrast key facts about Viatris Inc. (VTRS) and Pfizer Inc. (PFE).

Performance

VTRS vs. PFE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Viatris Inc. (VTRS) and Pfizer Inc. (PFE). The values are adjusted to include any dividend payments, if applicable.

VTRS vs. PFE - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
VTRS Viatris Inc.	9.44%	5.08%	19.68%	2.06%	-14.29%	-26.12%	18.16%
PFE Pfizer Inc.	14.66%	0.65%	-2.22%	-41.26%	-10.41%	66.70%	3.93%

Fundamentals

Market Cap VTRS : $15.57B PFE : $159.66B
EPS VTRS : -$3.02 PFE : $1.36
PS Ratio VTRS : 1.10 PFE : 2.56
PB Ratio VTRS : 1.06 PFE : 1.72
Total Revenue (TTM) VTRS : $14.30B PFE : $62.58B
Gross Profit (TTM) VTRS : $5.01B PFE : $44.01B
EBITDA (TTM) VTRS : -$1.13B PFE : $15.10B

Returns By Period

In the year-to-date period, VTRS achieves a 9.44% return, which is significantly lower than PFE's 14.66% return.

VTRS

• 1D: 4.24%
• 1M: -8.74%
• YTD: 9.44%
• 6M: 39.23%
• 1Y: 62.34%
• 3Y*: 17.13%
• 5Y*: 3.70%
• 10Y*: —

PFE

• 1D: 1.12%
• 1M: 1.56%
• YTD: 14.66%
• 6M: 14.02%
• 1Y: 18.86%
• 3Y*: -6.22%
• 5Y*: -0.14%
• 10Y*: 4.32%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

VTRS vs. PFE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

VTRS

VTRS Risk / Return Rank: 87
VTRS Sharpe Ratio Rank: 89
VTRS Sortino Ratio Rank: 86
VTRS Omega Ratio Rank: 85
VTRS Calmar Ratio Rank: 88
VTRS Martin Ratio Rank: 89

PFE

PFE Risk / Return Rank: 65
PFE Sharpe Ratio Rank: 67
PFE Sortino Ratio Rank: 61
PFE Omega Ratio Rank: 59
PFE Calmar Ratio Rank: 69
PFE Martin Ratio Rank: 69

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

VTRS vs. PFE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Viatris Inc. (VTRS) and Pfizer Inc. (PFE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	VTRS	PFE	Difference
Sharpe ratio Return per unit of total volatility	1.81	0.71	+1.10
Sortino ratio Return per unit of downside risk	2.47	1.17	+1.31
Omega ratio Gain probability vs. loss probability	1.32	1.15	+0.18
Calmar ratio Return relative to maximum drawdown	3.32	1.32	+2.00
Martin ratio Return relative to average drawdown	9.98	3.18	+6.80
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

VTRS vs. PFE - Sharpe Ratio Comparison

The current VTRS Sharpe Ratio is 1.81, which is higher than the PFE Sharpe Ratio of 0.71. The chart below compares the historical Sharpe Ratios of VTRS and PFE, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	VTRS	PFE	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.81	0.71	+1.10
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.11	-0.01	+0.12
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.18	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.03	0.26	-0.24

Correlation

The correlation between VTRS and PFE is 0.37, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

VTRS vs. PFE - Dividend Comparison

VTRS's dividend yield for the trailing twelve months is around 3.55%, less than PFE's 6.13% yield.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
VTRS Viatris Inc.	3.55%	3.86%	3.86%	4.43%	4.31%	2.44%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
PFE Pfizer Inc.	6.13%	6.91%	6.33%	5.70%	3.12%	2.64%	3.92%	3.68%	3.12%	3.53%	3.69%	3.47%

Drawdowns

VTRS vs. PFE - Drawdown Comparison

The maximum VTRS drawdown since its inception was -54.33%, smaller than the maximum PFE drawdown of -58.96%. Use the drawdown chart below to compare losses from any high point for VTRS and PFE.

Drawdown Indicators

	VTRS	PFE	Difference
Max Drawdown Largest peak-to-trough decline	-54.33%	-58.96%	+4.63%
Max Drawdown (1Y) Largest decline over 1 year	-18.97%	-12.59%	-6.38%
Max Drawdown (5Y) Largest decline over 5 years	-47.00%	-58.96%	+11.96%
Max Drawdown (10Y) Largest decline over 10 years	—	-58.96%	—
Current Drawdown Current decline from peak	-15.53%	-42.75%	+27.22%
Average Drawdown Average peak-to-trough decline	-31.63%	-17.33%	-14.30%
Ulcer Index Depth and duration of drawdowns from previous peaks	6.30%	6.13%	+0.17%

Volatility

VTRS vs. PFE - Volatility Comparison

Viatris Inc. (VTRS) has a higher volatility of 8.97% compared to Pfizer Inc. (PFE) at 6.75%. This indicates that VTRS's price experiences larger fluctuations and is considered to be riskier than PFE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	VTRS	PFE	Difference
Volatility (1M) Calculated over the trailing 1-month period	8.97%	6.75%	+2.22%
Volatility (6M) Calculated over the trailing 6-month period	23.30%	18.50%	+4.80%
Volatility (1Y) Calculated over the trailing 1-year period	34.59%	26.73%	+7.86%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	33.14%	25.46%	+7.68%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	33.89%	23.90%	+9.99%

Financials

VTRS vs. PFE - Profitability Comparison

The chart below illustrates the profitability comparison between Viatris Inc. and Pfizer Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

VTRS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Viatris Inc. reported a gross profit of 1.13B and revenue of 3.70B. Therefore, the gross margin over that period was 30.6%.

PFE - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Pfizer Inc. reported a gross profit of 12.29B and revenue of 17.56B. Therefore, the gross margin over that period was 70.0%.

VTRS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Viatris Inc. reported an operating income of -265.50M and revenue of 3.70B, resulting in an operating margin of -7.2%.

PFE - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Pfizer Inc. reported an operating income of 3.69B and revenue of 17.56B, resulting in an operating margin of 21.0%.

VTRS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Viatris Inc. reported a net income of -340.10M and revenue of 3.70B, resulting in a net margin of -9.2%.

PFE - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Pfizer Inc. reported a net income of -1.65B and revenue of 17.56B, resulting in a net margin of -9.4%.